Nine Stocks, Three Themes
Three themes, three timing buckets each
3×3
themes · buckets each
Some of these already made their move. Others are too big to make easy money.
Nine names across aerospace, energy and AI healthcare, three in each. All three themes are working. The question is not whether the theme is good, it is where each company sits in its own cycle.
Early
Story is bigger than the revenue. Something real has been built or signed, the money has not landed yet. You are paid to wait, and you carry the risk that waiting turns into never.
Right now
Revenue arrived. Price did not. The rarest of the three, because the proof already exists and you are simply earlier than the crowd.
Late
The easy money is gone. Not bad, just harder. A $2 trillion company needs another $2 trillion of buying to double. A $1.4 billion one needs $1.4 billion.
| Theme | Early | Right now | Late |
|---|---|---|---|
| Aerospace | HONAHoneywell Aerospace $158 · −28% |
ASTSAST SpaceMobile $59.73 · −55% |
SPCXSpaceX $151 · ~$2T |
| Energy | CSIQCanadian Solar $3.5B backlog |
VSTVistra $7.2B EBITDA mid |
BEBloom Energy $276 · +400% |
| AI Health | SDGRSchrödinger $19 · $1.4B |
TEMTempus AI $58.92 · −43% |
MRNAModerna +177% in one day |
Aerospace
SPCX · SpaceX · $151 · ~$2TLate
NumbersListed on Nasdaq 12 June 2026 at $135 and closed its first day at $161, a market value near $2.1 trillion. It raised roughly $75B. The stock now trades at $151, below that first-day close.
BullThe only listed pure play on launch, and on everything downstream of it. No competitor is close on cadence or on cost per kilogram to orbit, and the Starlink subscriber base compounds independently of the rocket business.
BearTo double, it has to add another $2 trillion of market value. Musk retains 82–85% of the voting power through the dual-class structure, so minority holders own the economics without any of the control.
ReadIt's too late to make easy money. For a double it would need to go from $2T to $4T. There are better risk to rewards.
HONA · Honeywell Aerospace · $158.26 · spun off June 2026Early
NumbersIts first report as a standalone company missed. Sales of $4.5B against $4.6B expected, operating profit of $995M against $1.1B, down 7% year over year. The stock fell more than 20%. Full-year organic growth guidance was cut from 7–9% to 4–5%, and EPS to $7.60–7.90 against a $8.86 consensus.
BullRead what actually caused the miss. Supply constraints, not weak demand. The company could not build fast enough, so it prioritised delivering engines to Boeing and Airbus, which pulled output away from its higher-margin aftermarket business. Orders were never the problem. It is now spending four times as much on multi-sourcing and in-sourcing to fix it.
BearSupply fixes take quarters, not weeks. A company three months old has already cut guidance once, and the diversion is hitting the most profitable line it has. Analyst targets of $213–225 against a $158 price assume a recovery nobody has seen evidence of yet.
ReadA supply problem is fixable. A demand problem is not. That distinction is what separates a bad quarter from a broken business, and this was a bad quarter.
ASTS · AST SpaceMobile · $59.73 · −55% from the highRight now
Numbers2026 revenue guided to $150–200M, targeting about $1B in 2027. Q2 revenue topped $30M, more than double Q1. $1.2B of contract commitments booked. Median analyst target $83. The stock peaked at $133.86 on 28 May 2026.
BullA five-fold revenue step in a single year, with the government line alone described as scaling into a recurring multibillion-dollar opportunity from 2027. Commercial service starts next year and the contracts are already signed.
BearDown 23% year to date for a reason. This is a satellite constellation that still has to be launched, and every quarter of delay pushes the ramp right. Capital intensity is brutal and dilution is the standing risk.
ReadThe largest forecast step-up of the nine, and the price has gone the other way all year. Down 55% from all-time highs.
Energy
BE · Bloom Energy · $275.75 · +400% in a yearLate
NumbersUp over 400% in twelve months on a 52-week range of $61 to $351. Revenue of $3.11B, up 91%, and now profitable at $245M. Joins the S&P 500 on 21 September. Trades at 332x trailing earnings, 78x forward.
BullFuel cells sited directly next to data centres, bypassing the grid interconnect queue entirely. That queue is the single hardest constraint every hyperscaler is hitting, and Bloom sells the way around it. Index inclusion forces passive buying.
BearThe average analyst target is $276, exactly where it trades. There is also an active securities class action over Chinese supply-chain risk disclosures, with a lead plaintiff deadline of 28 September.
ReadIt's up 50% from its $185 lows, it's too late to start chasing. The company is fundamentally sound, but there are better bets to take.
CSIQ · Canadian Solar · $3.5B storage backlogEarly
NumbersBattery storage shipments +73% year over year with an e-STORAGE contracted backlog of $3.5B. But Q2 revenue fell 29%, the company posted a $77M net loss, and management said the Jeffersonville cell ramp weighs on profitability for the rest of the year.
BullStorage is quietly becoming the company. Modules shrinking, storage compounding, 84 GWh of storage pipeline against 22 GWp of solar. And the polysilicon price floors that hit on 4 December raise every competitor's input cost.
Bear$7.1B of total debt against a small equity value, operations burning cash, and 45X tax-credit eligibility still unresolved. The backlog is real; whether the balance sheet survives to collect it is the question.
ReadThe reason to wait is the balance sheet. Profits genuinely do not arrive until 2027, and the debt load means the wait is not free. This is the riskiest of the nine.
VST · Vistra · 2026 EBITDA $6.8–7.6BRight now
Numbers2026 adjusted EBITDA guided to $6.8–7.6B, midpoint $7.2B. Q2 adjusted EBITDA up 31%. The 2027 opportunity range is already set at $7.4–7.8B.
BullThe most direct way to own AI without owning a chip. Data centres need power they cannot generate, Vistra owns generation that cannot be replicated quickly, and the Ratepayer Pledge binds hyperscalers to pay for their own power and grid upgrades.
BearPower prices are cyclical and hedges cut both ways. Q2 EBITDA rose 31% despite hedge losses. Regulators can intervene in merchant pricing at any time, and the trade is now consensus.
ReadThe safest right-now name here, and the only one with a forward number already in writing. Guidance reaffirmed twice this year means the figure is not a hope. It is a plan being executed.
AI Healthcare
MRNA · Moderna · +177% in one dayLate
Numbers+176.97% on 19 August 2026, its largest single-day gain on record, on Phase 3 melanoma data with Merck. $44B of market value added in one session, on volume 1,819% above its three-month average. Up 123% over the following month.
BullThe personalised cancer vaccine thesis just cleared Phase 3. If the result reads across to other tumour types, the mRNA platform is worth more than the vaccine business ever was.
BearYou would be buying from people who held it through the entire drawdown. One data readout re-rated the whole company, and the next one can do exactly the reverse.
ReadAfter 177% in a day it's better to look for other plays in AI health that have yet to move up. Potentially buy on pullbacks.
SDGR · Schrödinger · $19.02 · $1.42BEarly
NumbersTrailing revenue of $255.87M against a $1.42B market value. Still lossmaking. Average analyst target $21.43, roughly 13% above the price.
BullPhysics-based drug design that demonstrably works. The software is licensed by large pharma, and the company holds equity stakes in drugs it helps design. Two ways to win off one platform.
BearSix years public and still not profitable. The co-development stakes are lottery tickets on someone else's clinical trials, and the software business alone does not carry the multiple.
ReadThe cleanest small-position case of the nine. At $1.4B it is small enough that one drug working changes everything, and small enough that being wrong costs a position, not a portfolio.
TEM · Tempus AI · $58.92 · −43% from the highRight now
NumbersTrading at $58.92 against a high of $104.32, down roughly 43%. Posted its first profitable quarter in Q2 2026, GAAP net income of $5.6M against a $42.8M loss a year earlier. Also buying Personalis for $1.5B in stock.
BullThe deepest library of linked clinical and molecular data in oncology, which is the hard part to replicate. Personalis adds minimal residual disease testing, the highest-value recurring test in cancer care.
BearCheck the quality of that profit. $97.4M of it was a non-cash mark-to-market gain on securities it holds, and the operating line still lost money. The $1.5B all-stock deal also dilutes, which is why the stock fell on it.
ReadDown 43% from all-time highs, and the one AI health name most likely to find success from their monopoly over information. And they just turned profitable.
Not financial advice. Please do your own research.
Want to see what stocks I'm watching next?
Join the Discord to find out! →discord.gg/nfrs · @Nefarioustrading
Nefarious Trading
Equity research and trading commentary. AI infrastructure, semiconductors, aerospace, energy, commodities.
Sources
Figures are company disclosures and market data as of 13 September 2026. SpaceX listed 12 June 2026 on Nasdaq; Honeywell Aerospace completed its spin-off and began trading late June 2026. ASTS revenue guidance and contract commitments are from the company's Q2 2026 disclosures; the $83 figure is the median analyst 12-month target. Vistra's EBITDA ranges are company guidance, reaffirmed through Q2 2026. Moderna's 19 August move and Tempus AI's Personalis transaction are as reported.
Whose opinion is whose: the EARLY / RIGHT NOW / LATE call and the Read line on each name are John's. The Numbers rows are sourced company data; Bull and Bear are my framing of it.
Figures are company disclosures and market data as of 13 September 2026. SpaceX listed 12 June 2026 on Nasdaq; Honeywell Aerospace completed its spin-off and began trading late June 2026. ASTS revenue guidance and contract commitments are from the company's Q2 2026 disclosures; the $83 figure is the median analyst 12-month target. Vistra's EBITDA ranges are company guidance, reaffirmed through Q2 2026. Moderna's 19 August move and Tempus AI's Personalis transaction are as reported.
Whose opinion is whose: the EARLY / RIGHT NOW / LATE call and the Read line on each name are John's. The Numbers rows are sourced company data; Bull and Bear are my framing of it.
One trader's view, not investment advice. Do your own research. Bucket calls are opinion; every figure is date-stamped above.